A new white paper by Karen Mulligan provides historic context and puts the pitfalls and promise of the 340B drug pricing program into perspective. Her analysis also suggests how the program can be modified to better serve its aims of stretching federal dollars to better serve patients in need.
Other featured articles
Private Equity Investment as a Divining Rod for Market Failure: Policy Responses to Harmful Physician Practice Acquisitions
It is unclear whether private equity investment is itself a problem or whether, in the absence of private equity, other sources of capital—such as public equity, venture capital, health systems, and insurers—would similarly exploit existing market failures and legal loopholes in the healthcare system.
The Social Value of Disseminating Transcatheter Aortic Valve Replacement
Transcatheter aortic valve replacement (TAVR) has facilitated treatment of aortic stenosis in patients otherwise ineligible for corrective surgery or who are reluctant to undergo open-heart surgery. Schaeffer Center experts estimate the social value of past and future TAVR procedures.
Advancing the Economics of Palliative Care: The Value to Individuals and Families, Organizations, and Society
A palliative care research agenda can help lay the foundation for building a strong evidence base to guide public policies meant to advance affordable, equitable, high-quality, patient-centered care.
Reducing Racial Disparities in Early Cancer Diagnosis With Blood-Based Tests
A new white paper published by the USC Schaeffer Center focuses on multi-cancer, early detection, (MCED) blood-based tests as one solution to reduce disparities in late-stage cancer diagnosis among minority populations.